BETAMETHASONE VALERATE (betamethasone valerate) by Sandoz is clinical pharmacology: topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. First approved in 1983.
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
Betamethasone valerate is a topical corticosteroid ointment that reduces inflammation, itching, and redness through anti-inflammatory and vasoconstrictor mechanisms. It is absorbed percutaneously and metabolized hepatically, with efficacy correlating to vasoconstrictor potency. This product treats inflammatory skin conditions where topical steroid therapy is indicated.
As a legacy product approaching loss of exclusivity with modest Part D claims, this brand operates with likely lean commercial teams focused on cost management and generic transition planning.
CLINICAL PHARMACOLOGY: Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on BETAMETHASONE VALERATE at Sandoz? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on betamethasone valerate offers limited career growth opportunity as a mature, generic-competitive product with minimal innovation pipeline. Roles focus on market defense, cost management, and transition strategy rather than new indication expansion or commercial launch.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo